A number of other equities research analysts have also recently commented on the stock. Raymond James restated a buy rating and set a $21.00 target price on shares of Colfax in a research note on Thursday, May 2nd. Jefferies Financial Group set a $150.00 target price on shares of Amedisys and gave the stock a buy rating in a research note on Monday. Barclays set a €77.00 ($89.53) price objective on shares of HeidelbergCement and gave the company a buy rating in a research report on Thursday, March 21st. Finally, ValuEngine upgraded shares of Zumiez from a sell rating to a hold rating in a research report on Saturday, June 22nd. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $131.43.
Shares of NASDAQ:AMED opened at $123.00 on Tuesday. The business has a 50 day simple moving average of $117.47. Amedisys has a twelve month low of $92.08 and a twelve month high of $140.91. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market cap of $3.87 billion, a PE ratio of 33.88, a PEG ratio of 1.50 and a beta of 1.34.
Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, April 30th. The health services provider reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.22. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The company had revenue of $467.34 million for the quarter, compared to analysts’ expectations of $460.83 million. During the same quarter last year, the business earned $0.79 EPS. The firm’s revenue was up 17.0% compared to the same quarter last year. Equities analysts forecast that Amedisys will post 4.08 earnings per share for the current year.
In related news, CFO Scott G. Ginn sold 4,872 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $118.50, for a total value of $577,332.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David L. Kemmerly sold 8,125 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $117.77, for a total transaction of $956,881.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 45,028 shares of company stock valued at $5,210,707. 2.90% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of AMED. Alpha Quant Advisors LLC boosted its stake in Amedisys by 137.0% during the first quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock worth $29,000 after buying an additional 137 shares during the period. Captrust Financial Advisors boosted its stake in Amedisys by 161.8% during the fourth quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock worth $70,000 after buying an additional 369 shares during the period. Meeder Asset Management Inc. boosted its stake in Amedisys by 102.3% during the first quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock worth $120,000 after buying an additional 488 shares during the period. National Asset Management Inc. purchased a new position in Amedisys during the first quarter worth $211,000. Finally, Victory Capital Management Inc. purchased a new position in Amedisys during the first quarter worth $213,000. 86.30% of the stock is owned by institutional investors.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
See Also: Options Trading
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.